totally devoted to this concept of that. >> good to point out that the drug market overall weaker glaxonds out in part because of the concern about upcoming litigation or trial. but merck is down, pfizer is down, j&j. >> j&j has exposure. but exposure is exposure i think they're taking the money that they're getting correctly from covid and buying new companies and developing a pipeline >> yeah. but losing the surplus so to speak. >> yes >> of revenue from the covid vaccine, not to mention paxlovid and the global blood is the latest deal. $5 billion -- >> yeah. >> bio -- >> i'm sorry, sickle cell anemia >> bio grade at almost called a one a day -- a migraine with the weather, it will get rid of the migraine in a half hour. people don't know about it yet the ceo told it to pfizer in part because he felt the word wasn't going to get out. pfizer is committed to making a $15 billion drug >> right, biohaven is going to be own the by pfizer this year is not, last year was a great year for that stock. >> yeah. >> and finally pushing it above its 20-year r-- for 20 years tht stock has not done

i mean you've got glaxo down 6.7%, pfizer and others down 3.5% and started on tuesday when a ubs analyst downgraded from a neutral to a buy from the ongoing legal action and lawsuits swirling around zantac, which has been sold at different times in various forms by drug makers. let's look at sono shares, they're off key after the maker of high end speakers lowered full year guidance and announced the upcoming departure of cfo. shares areplummetting down 25% and forecast coming ahead of crucial holiday season as americans cut back on high ticket discretionary items. tvs, electronics included, but they are not cuts back on home furnishings, at least not the ones made by our house. shares of the furniture maker surging 22.5% right now after the company reported second quarter earnings that beat wall street expectations and high end furnishings company raised its full year outlook and they're not the only ones from couch to bed, temper shareholders, probably going to sleep well tonight. pretty well. stocks up 2.8% and shares of the mattress maker on the move after golden sacshs initiated the

it spun off from glaxo, so whenever you get a spinoff of the first months, this is the only large pure play consumer health care space. that space by itself grows 4 to 6% a year, but the margins are very high. this company's going to have close to 2.5% dividend, and really they have so much wood to chop here. they've got good products, like advil, things like that where people, the demand for that is inelastic. it trades at 14 times earnings, the closest comp to it is p&g at 25 once the sellers kind of move out of the way, we like companies like this that are under appreciated, not even, you know, understood at this point in a space that as we go through some choppiness and volatility in the market, you want to own strong cash flows. >> sarat, always great to sea you, sir sarat sethi, we appreciate it. >> always has interesting ideas, too, not necessarily names we talk about all the time. >>> investors may have thought tech was having an all clear moment as it led the recovery from june lows this week may be showing that things aren't as rosy for the sector as many thought the nasdaq d